vs
Side-by-side financial comparison of GSK plc (GSK) and MAINZ BIOMED N.V. (MYNZ). Click either name above to swap in a different company.
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
Mainz Biomed N.V. is a molecular diagnostics company specializing in the development and commercialization of non-invasive early detection tests for gastrointestinal cancers, primarily colorectal cancer. Its flagship product ColoAlert is approved and available across European markets, with active expansion initiatives targeting North America and other global regions.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 23 | — | $214.8K | ||
| Q3 23 | — | $181.7K | ||
| Q2 23 | — | $248.9K | ||
| Q1 23 | — | $1 | ||
| Q3 22 | — | $96.8K | ||
| Q2 22 | — | $139.2K |
| Q4 23 | — | — | ||
| Q3 23 | — | $-6.3M | ||
| Q2 23 | — | $-8.3M | ||
| Q1 23 | — | $-6.6M | ||
| Q3 22 | — | $-5.6M | ||
| Q2 22 | — | $-6.9M |
| Q4 23 | — | 62.7% | ||
| Q3 23 | — | 48.0% | ||
| Q2 23 | — | 59.8% | ||
| Q1 23 | — | — | ||
| Q3 22 | — | 19.2% | ||
| Q2 22 | — | 58.0% |
| Q4 23 | — | — | ||
| Q3 23 | — | -3104.9% | ||
| Q2 23 | — | -3183.9% | ||
| Q1 23 | — | -648755600.0% | ||
| Q3 22 | — | -5657.1% | ||
| Q2 22 | — | -4989.9% |
| Q4 23 | — | — | ||
| Q3 23 | — | -3467.7% | ||
| Q2 23 | — | -3314.7% | ||
| Q1 23 | — | -656091600.0% | ||
| Q3 22 | — | -5781.8% | ||
| Q2 22 | — | -4983.3% |
| Q4 23 | — | — | ||
| Q3 23 | — | $-0.39 | ||
| Q2 23 | — | $-0.56 | ||
| Q1 23 | — | $-0.45 | ||
| Q3 22 | — | $-0.39 | ||
| Q2 22 | — | $-0.48 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
